About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
University of Miami's 2nd Biennial Miami Leukemia Symposium
AML Biology and Treatment
MDS Biology and Treatment
ALL Biology and Treatment
CLL Therapy in 2019
CML and MPNs: Final Frontiers and New Breakthroughs
Myeloid Biology and Novel Therapies
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
T
2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant MDS?
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Timothy Graubert
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Timothy Graubert
3 views
October 23, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
MDS Biology and Treatment
25:42
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on MDS Mutational Landscape: What Are the Most Common MD…
Feat.
R. Bejar
20:06
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…
Feat.
T. Graubert
22:02
University of Miami's 2nd Biennial Miami Leukemia Symposium
TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…
Feat.
A. Verma
12:19
University of Miami's 2nd Biennial Miami Leukemia Symposium
How to Calculate Risk in MDS Patients?
Feat.
M. Sekeres
14:36
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Leveling Lower-risk MDS
Feat.
M. Sekeres
05:28
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Hampering Higher-risk MDS
Feat.
M. Sekeres
10:48
University of Miami's 2nd Biennial Miami Leukemia Symposium
Hypomethylating Agents as SoC in MDS/AML: Clearance of TP53 Mutation…
Feat.
D. Sallman
08:13
University of Miami's 2nd Biennial Miami Leukemia Symposium
Discussion on the Data of Frontline Combination Therapy with APR-246…
Feat.
D. Sallman
05:21
University of Miami's 2nd Biennial Miami Leukemia Symposium
Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Chec…
Feat.
D. Sallman
27:33
University of Miami's 2nd Biennial Miami Leukemia Symposium
Overcoming Adaptive Therapy Resistance in AML: IRAK Signalling (via …
Feat.
D. Starczynowski
